Biomarker Guided Treatment in Gynaecological Cancer
Recruiting
Phase 4
Interventional Study
Endometrial Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 95
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,300 (estimated)
- Sponsor
- Haukeland University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series.
Part 1: Performance of a ph…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria part 1:
All patients referred to a participating research centre with suspicion of or confirmed endometrial cancer.
Exclusion Criteria part 1:
1. Patients who do not have endometrial cancer
2. Patients who will or cannot give informed consent (including language barriers)
3. Pa…
Contacts